Free Access
Issue
Med Sci (Paris)
Volume 22, Number 8-9, Août–Septembre 2006
Page(s) 683 - 685
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20062289683
Published online 15 August 2006
  1. Lotersztajn S, Julien B, Teixeira-Clerc F, et al. Hepatic fibrosis : molecular mechanisms and drug targets. Annu Rev Pharmacol Toxicol 2005; 45 : 605–28. [Google Scholar]
  2. Mallat A, Lotersztajn S. Endocannabinoids as novel mediators of liver diseases. J Endocrinol Invest 2006; 29 : 58–65. [Google Scholar]
  3. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3 : 771–84. [Google Scholar]
  4. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients : 1-year experience from the RIO-Europe study. Lancet 2005; 365 : 1389–97. [Google Scholar]
  5. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353 : 2121–34. [Google Scholar]
  6. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 2005; 434 : 782–6. [Google Scholar]
  7. Ofek O, Karsak M, Leclerc N, et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 2006; 103 : 696–701. [Google Scholar]
  8. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128 : 742–55. [Google Scholar]
  9. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism : a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12 : 671–6. [Google Scholar]
  10. Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42 : 63–71. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.